Beta Bionics, Inc.: Divisadero Street Capital Management, LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Divisadero Street Capital Management amended its Schedule 13G filing on Beta Bionics, disclosing a revised passive stake in the insulin delivery device maker. The update, filed with the SEC under accession number 0000919574-26-008148, revises the fund's previously reported beneficial ownership position. Schedule 13G amendments are typically triggered when a holder's stake crosses or adjusts past the 5% threshold or when holdings change materially. The filing signals continued institutional interest in Beta Bionics, which develops automated insulin delivery systems. Investors will watch for the specific share count and percentage in the amended document, and any further 13G or 13D activity that could indicate a shift from passive to active positioning.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Beta Bionics, Inc., Divisadero Street Capital Management, LP